Premium
RGD‐based PET tracers for imaging receptor integrin α v β 3 expression
Author(s) -
Cai Hancheng,
Conti Peter S
Publication year - 2013
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2999
Subject(s) - positron emission tomography , chemistry , pet imaging , integrin , molecular imaging , receptor expression , in vivo , receptor , cancer research , nuclear medicine , biochemistry , medicine , biology , microbiology and biotechnology
Positron emission tomography (PET) imaging of receptor integrin α v β 3 expression may play a key role in the early detection of cancer and cardiovascular diseases, monitoring disease progression, evaluating therapeutic response, and aiding anti‐angiogenic drugs discovery and development. The last decade has seen the development of new PET tracers for in vivo imaging of integrin α v β 3 expression along with advances in PET chemistry. In this review, we will focus on the radiochemistry development of PET tracers based on arginine–glycine–aspartic acid (RGD) peptide, present an overview of general strategies for preparing RGD‐based PET tracers, and review the recent advances in preparations of 18 F‐labeled, 64 Cu‐labeled, and 68 Ga‐labeled RGD tracers, RGD‐based PET multivalent probes, and RGD‐based PET multimodality probes for imaging receptor integrin α v β 3 expression.